X

Drug Profile

DTx 1252

Alternative Names: DTx-1252

Latest Information Update: 19 Jul 2023

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator DTx Pharma
Class Small interfering RNA
Mechanism of Action PMP22 protein inhibitors; RNA interference

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Charcot-Marie-Tooth disease
New Molecular Entity Yes

Highest Development Phases

Preclinical Charcot-Marie-Tooth disease

Most Recent Events

17 Jul 2023 DTx Pharma has been acquired by Novartis
07 Jun 2023 DTx 1252 receives Orphan Drug status for Charcot-Marie-Tooth disease in USA
28 Nov 2022 DTx Pharma plans clinical development of DTx 1252 for Charcot-Marie-tooth disease in 2023 (DTx Pharma pipeline, November 2022)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com